Koligo Therapeutics

Louisville, United States Founded: 2016 • Age: 10 yrs Acquired By Orgenesis
Developer of trans-formative cell therapies for treating chronic pancreatitis and Type I diabetes

About Koligo Therapeutics

Koligo Therapeutics is a company based in Louisville (United States) founded in 2016 was acquired by Orgenesis in September 2020.. Koligo Therapeutics has raised $3.65 million across 2 funding rounds from investors including Orgenesis. Koligo Therapeutics operates in a competitive market with competitors including Neurocrine, Crinetics, Sana Biotechnology, Semma Therapeutics and Adocia, among others.

  • Headquarter Louisville, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $3.65 M (USD)

    in 2 rounds

  • Latest Funding Round
    $1.65 M (USD), Seed

    Oct 06, 2020

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Orgenesis

    (Sep 29, 2020)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Koligo Therapeutics

Koligo Therapeutics has successfully raised a total of $3.65M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.65 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Seed — $1.6M
  • First Round

    (06 Mar 2018)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2020 Amount Seed - Koligo Therapeutics Valuation

investors

Mar, 2018 Amount Seed - Koligo Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Koligo Therapeutics

Koligo Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Orgenesis. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Cell and gene therapies for multiple disorders are developed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Koligo Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Koligo Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Koligo Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Koligo Therapeutics

Koligo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Crinetics, Sana Biotechnology, Semma Therapeutics and Adocia, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of small molecule therapeutics for endocrine and CNS disorders
domain founded_year HQ Location
Developer of therapies for the treatment of endocrine-related diseases and cancers
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
domain founded_year HQ Location
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
domain founded_year HQ Location
Therapeutics for diabetes and obesity treatment are developed.
domain founded_year HQ Location
Therapies for metabolic and orphan diseases are developed by Rezolute.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Koligo Therapeutics

Frequently Asked Questions about Koligo Therapeutics

When was Koligo Therapeutics founded?

Koligo Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Koligo Therapeutics located?

Koligo Therapeutics is headquartered in Louisville, United States. It is registered at Louisville, Kentucky, United States.

Is Koligo Therapeutics a funded company?

Koligo Therapeutics is a funded company, having raised a total of $3.65M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Mar 06, 2018.

What does Koligo Therapeutics do?

Koligo Therapeutics is developing trans-formative cell therapies for treating chronic pancreatitis and Type I diabetes. Their lead candidate, Kyslecel (infused into the liver), which is made from autologous pancreatic islets. The candidate has complete clinical studies and ready to be marketed. It is used for treating chronic pancreatitis.

Who are the top competitors of Koligo Therapeutics?

Koligo Therapeutics's top competitors include Crinetics, Neurocrine and Sana Biotechnology.

Who are Koligo Therapeutics's investors?

Koligo Therapeutics has 1 investor. Key investors include Orgenesis.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available